Aducanumab has been a hot topic in the field of dementia and Alzheimer’s disease. Aducanumab, also known as Aduhelm, is a new Alzheimer’s drug for people with Alzheimer’s disease in their early stages with mild cognitive impairment. With so many questions, it helps to have answers from experts like Dr. Jason Karlawish, Neurologist and Co-Director of the Penn Memory Center
In this episode, Dr. Karlawish and I discuss:
- Reasons that Dr. Karlawish is a “reluctant prescriber” of Aducanumab
- The risks and benefits of Aducanumab for Alzheimer’s Disease
- How the FDA made the decision to approve Aducanumab for use
- The answer to the question: “is some hope is better than no hope?” (related to the use of Aducanumab for Alzheimers.)
- The effects of the COVID-19 virus on brain health (i.e., risk for dementia)
- The difference between FDA approval for Aducanumab versus COVID-19 vaccine
Dr. Regina Koepp is a board certified clinical psychologist, clinical geropsychologist, and founder and CEO of the Center for Mental Health & Aging: the “go to” place for mental health and aging. Dr. Koepp is a sought after speaker on the topics of mental health and aging, caregiving, ageism, resilience, intimacy in the context of life altering Illness, and dementia and sexual expression. Dr. Koepp is on a mission to ensure mental health and belonging for older adults, because every person at every age is worthy of healing, transformation, and love. Learn more about Dr. Regina Koepp here.
Regina Koepp, PsyD, ABPP
Want More? Listen to Our Most Recent Episodes
Older adults deserve high quality mental health care.
Therapists deserve the training to provide that care.
